Long-term mortality in patients with severe secondary mitral regurgitation and normal left ventricular ejection fraction: interventional perspective

EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
Amr F BarakatSamir R Kapadia

Abstract

Patients with severe secondary mitral regurgitation (MR) and normal ejection fraction are being excluded from clinical trials evaluating transcatheter mitral devices. We sought to evaluate the long-term mortality with medical management alone in this patient population. We retrospectively evaluated patients diagnosed with ≥3+ MR at our institution over 15 years. Only patients with an ejection fraction ≥60% were included in the study. Those with degenerative mitral valve disease, papillary muscle dysfunction, or hypertrophic cardiomyopathy, and those who underwent mitral valve intervention were excluded. The study included 400 patients (age 71.1±14.8, 25.1% male, ejection fraction 62.5±3.6%). Mechanism of secondary MR was restricted valve motion, annular dilation and apical tethering in 91.5, 4.5 and 4%, respectively. One-year and three-year mortality were 19.1 and 26.3%, respectively. On multivariable Cox proportional regression analysis, older age, New York Heart Association functional Class III or IV, >3+ MR and larger left atrium were independent predictors of mortality. Severe secondary MR with normal left ventricular systolic function has significant mortality with medical management alone. This initial observation needs t...Continue Reading

References

Jul 1, 1967·Circulation Research·E H SonnenblickT Cooper
Jul 2, 2003·Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography·William A ZoghbiUNKNOWN American Society of Echocardiography
Sep 19, 2006·Lancet·Vuyisile T NkomoMaurice Enriquez-Sarano
Sep 24, 2011·Journal of the American College of Cardiology·Zachary M GertzFrank E Silvestry
Aug 28, 2012·European Heart Journal·UNKNOWN Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC)Marian Zembala
Apr 13, 2013·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·Wolfgang SchillingerGerd Hasenfuß
Jun 5, 2013·European Heart Journal Cardiovascular Imaging·Patrizio LancellottiUNKNOWN Scientific Document Committee of the European Association of Cardiovascular Imaging
Oct 23, 2013·European Heart Journal Cardiovascular Imaging·Liam RingBushra S Rana
Aug 30, 2014·Journal of the American College of Cardiology·Georg NickenigUNKNOWN Transcatheter Valve Treatment Sentinel Registry Investigators of the EURObservational Research Programme of the European Soc
Jan 7, 2015·Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography·Roberto M LangJens-Uwe Voigt
Mar 31, 2015·Journal of the American College of Cardiology·Anita W AsgarGregg W Stone

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.